179 related articles for article (PubMed ID: 25125725)
21. Faster T-cell development following gene therapy compared with haploidentical HSCT in the treatment of SCID-X1.
Touzot F; Moshous D; Creidy R; Neven B; Frange P; Cros G; Caccavelli L; Blondeau J; Magnani A; Luby JM; Ternaux B; Picard C; Blanche S; Fischer A; Hacein-Bey-Abina S; Cavazzana M
Blood; 2015 Jun; 125(23):3563-9. PubMed ID: 25869287
[TBL] [Abstract][Full Text] [Related]
22. Intravenous injection of a foamy virus vector to correct canine SCID-X1.
Burtner CR; Beard BC; Kennedy DR; Wohlfahrt ME; Adair JE; Trobridge GD; Scharenberg AM; Torgerson TR; Rawlings DJ; Felsburg PJ; Kiem HP
Blood; 2014 Jun; 123(23):3578-84. PubMed ID: 24642749
[TBL] [Abstract][Full Text] [Related]
23. Ten years of gene therapy for primary immune deficiencies.
Aiuti A; Roncarolo MG
Hematology Am Soc Hematol Educ Program; 2009; ():682-9. PubMed ID: 20008254
[TBL] [Abstract][Full Text] [Related]
24. Retrovirus-induced oncogenesis and safety of retroviral vectors.
Nair V
Curr Opin Mol Ther; 2008 Oct; 10(5):431-8. PubMed ID: 18830918
[TBL] [Abstract][Full Text] [Related]
25. Methodology and software to detect viral integration site hot-spots.
Presson AP; Kim N; Xiaofei Y; Chen IS; Kim S
BMC Bioinformatics; 2011 Sep; 12():367. PubMed ID: 21914224
[TBL] [Abstract][Full Text] [Related]
26. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study.
Ferrua F; Cicalese MP; Galimberti S; Giannelli S; Dionisio F; Barzaghi F; Migliavacca M; Bernardo ME; Calbi V; Assanelli AA; Facchini M; Fossati C; Albertazzi E; Scaramuzza S; Brigida I; Scala S; Basso-Ricci L; Pajno R; Casiraghi M; Canarutto D; Salerio FA; Albert MH; Bartoli A; Wolf HM; Fiori R; Silvani P; Gattillo S; Villa A; Biasco L; Dott C; Culme-Seymour EJ; van Rossem K; Atkinson G; Valsecchi MG; Roncarolo MG; Ciceri F; Naldini L; Aiuti A
Lancet Haematol; 2019 May; 6(5):e239-e253. PubMed ID: 30981783
[TBL] [Abstract][Full Text] [Related]
27. Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity.
Wu C; Dunbar CE
Front Med; 2011 Dec; 5(4):356-71. PubMed ID: 22198747
[TBL] [Abstract][Full Text] [Related]
28. Immune Reconstitution After Gene Therapy Approaches in Patients With X-Linked Severe Combined Immunodeficiency Disease.
Blanco E; Izotova N; Booth C; Thrasher AJ
Front Immunol; 2020; 11():608653. PubMed ID: 33329605
[TBL] [Abstract][Full Text] [Related]
29. Gene therapy for primary adaptive immune deficiencies.
Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M
J Allergy Clin Immunol; 2011 Jun; 127(6):1356-9. PubMed ID: 21624615
[TBL] [Abstract][Full Text] [Related]
30. Biosafety challenges for use of lentiviral vectors in gene therapy.
Rothe M; Modlich U; Schambach A
Curr Gene Ther; 2013 Dec; 13(6):453-68. PubMed ID: 24195603
[TBL] [Abstract][Full Text] [Related]
31. Pretransplant mobilization with granulocyte colony-stimulating factor improves B-cell reconstitution by lentiviral vector gene therapy in SCID-X1 mice.
Huston MW; Riegman AR; Yadak R; van Helsdingen Y; de Boer H; van Til NP; Wagemaker G
Hum Gene Ther; 2014 Oct; 25(10):905-14. PubMed ID: 25222508
[TBL] [Abstract][Full Text] [Related]
32. The evolution of gene therapy in X-linked severe combined immunodeficiency.
Rans TS; England R
Ann Allergy Asthma Immunol; 2009 May; 102(5):357-62; quiz 363-5, 402. PubMed ID: 19492655
[TBL] [Abstract][Full Text] [Related]
33. [Gene therapy of SCID-X1].
Baum C; Schambach A; Modlich U; Thrasher A
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2007 Dec; 50(12):1507-17. PubMed ID: 18046520
[TBL] [Abstract][Full Text] [Related]
34. New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy.
Pike-Overzet K; van der Burg M; Wagemaker G; van Dongen JJ; Staal FJ
Mol Ther; 2007 Nov; 15(11):1910-6. PubMed ID: 17726455
[TBL] [Abstract][Full Text] [Related]
35. Promoter competition for gene therapy of SCID-X1.
Baum C; Schambach A
Hum Gene Ther; 2011 Mar; 22(3):255-6. PubMed ID: 21401346
[No Abstract] [Full Text] [Related]
36. Gene therapy for SCID-X1: focus on clinical data.
Baum C
Mol Ther; 2011 Dec; 19(12):2103-4. PubMed ID: 22134740
[No Abstract] [Full Text] [Related]
37. Biosafety considerations using gamma-retroviral vectors in gene therapy.
Deichmann A; Schmidt M
Curr Gene Ther; 2013 Dec; 13(6):469-77. PubMed ID: 24195605
[TBL] [Abstract][Full Text] [Related]
38. New Gene Therapy Potential Cure for "Bubble Boy Disease": An experimental gene therapy has allowed children with SCID-1X to develop fully functioning immune systems.
Am J Med Genet A; 2019 Jul; 179(7):1114-1115. PubMed ID: 31180192
[No Abstract] [Full Text] [Related]
39. In-Vivo Gene Therapy with Foamy Virus Vectors.
Rajawat YS; Humbert O; Kiem HP
Viruses; 2019 Nov; 11(12):. PubMed ID: 31771194
[TBL] [Abstract][Full Text] [Related]
40. Parachuting in the epigenome: the biology of gene vector insertion profiles in the context of clinical trials.
Baum C
EMBO Mol Med; 2011 Feb; 3(2):75-7. PubMed ID: 21254403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
